- Home
- GDYN vs TNGX Comparison
GDYN vs TNGX Comparison
Compare GDYN & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDYN
- TNGX
- Stock Information
- Founded
- GDYN 2006
- TNGX 2014
- Country
- GDYN United States
- TNGX United States
- Employees
- GDYN N/A
- TNGX N/A
- Industry
- GDYN Computer Software: Prepackaged Software
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- GDYN Technology
- TNGX Health Care
- Exchange
- GDYN Nasdaq
- TNGX Nasdaq
- Market Cap
- GDYN 701.9M
- TNGX 723.2M
- IPO Year
- GDYN N/A
- TNGX N/A
- Fundamental
- Price
- GDYN $7.77
- TNGX $7.87
- Analyst Decision
- GDYN Strong Buy
- TNGX Strong Buy
- Analyst Count
- GDYN 4
- TNGX 6
- Target Price
- GDYN $15.75
- TNGX $10.00
- AVG Volume (30 Days)
- GDYN 1.1M
- TNGX 1.7M
- Earning Date
- GDYN 10-30-2025
- TNGX 11-05-2025
- Dividend Yield
- GDYN N/A
- TNGX N/A
- EPS Growth
- GDYN N/A
- TNGX N/A
- EPS
- GDYN 0.19
- TNGX N/A
- Revenue
- GDYN $389,227,000.00
- TNGX $24,296,000.00
- Revenue This Year
- GDYN $20.71
- TNGX $20.42
- Revenue Next Year
- GDYN $10.71
- TNGX N/A
- P/E Ratio
- GDYN $40.23
- TNGX N/A
- Revenue Growth
- GDYN 22.27
- TNGX N/A
- 52 Week Low
- GDYN $7.37
- TNGX $1.03
- 52 Week High
- GDYN $25.50
- TNGX $8.98
- Technical
- Relative Strength Index (RSI)
- GDYN 42.91
- TNGX 66.70
- Support Level
- GDYN $7.46
- TNGX $6.38
- Resistance Level
- GDYN $7.82
- TNGX $6.90
- Average True Range (ATR)
- GDYN 0.30
- TNGX 0.46
- MACD
- GDYN 0.06
- TNGX 0.09
- Stochastic Oscillator
- GDYN 42.11
- TNGX 90.50
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.